Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin for Non-blood Candida Infections
NCT00083343Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- May 2004
- Primary completion
- Feb 2006
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of caspofungin in invasive candidiasis, sponsored by Merck & Co. Primary endpoint: Favorable overall response rate. Started May 2004; status: completed.
02
Drugs
caspofungin
03
Conditions
invasive candidiasis
Beyond the preview
Go deeper on NCT00083343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083343.